Kingswood Wealth Advisors LLC Has $1.12 Million Holdings in Abbott Laboratories $ABT

Key Points

• Kingswood Wealth Advisors LLC reduced its holdings in Abbott Laboratories by 70.3% during Q2, owning 8,221 shares valued at approximately $1.12 million at the end of the quarter.
• Abbott Laboratories has a strong presence among institutional investors, who collectively own 75.18% of the company’s stock.
• The company recently declared a $0.59 quarterly dividend, with a payout ratio of 29.57% and an annual yield of 1.8%.

Kingswood Wealth Advisors LLC lessened its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 70.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,221 shares of the healthcare product maker's stock after selling 19,461 shares during the period. Kingswood Wealth Advisors LLC's holdings in Abbott Laboratories were worth $1,118,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. TriaGen Wealth Management LLC grew its position in Abbott Laboratories by 7.6% in the second quarter. TriaGen Wealth Management LLC now owns 1,665 shares of the healthcare product maker's stock valued at $226,000 after acquiring an additional 118 shares during the last quarter. Joel Isaacson & Co. LLC grew its position in Abbott Laboratories by 25.9% in the second quarter. Joel Isaacson & Co. LLC now owns 5,150 shares of the healthcare product maker's stock valued at $700,000 after acquiring an additional 1,058 shares during the last quarter. Roundview Capital LLC grew its position in Abbott Laboratories by 3.9% in the second quarter. Roundview Capital LLC now owns 11,841 shares of the healthcare product maker's stock valued at $1,610,000 after acquiring an additional 445 shares during the last quarter. Sunbeam Capital Management LLC grew its position in Abbott Laboratories by 13.3% in the second quarter. Sunbeam Capital Management LLC now owns 1,936 shares of the healthcare product maker's stock valued at $263,000 after acquiring an additional 227 shares during the last quarter. Finally, Tyche Wealth Partners LLC grew its position in Abbott Laboratories by 5.5% in the second quarter. Tyche Wealth Partners LLC now owns 12,131 shares of the healthcare product maker's stock valued at $1,650,000 after acquiring an additional 629 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $134.45 on Thursday. The business's 50 day simple moving average is $132.30 and its 200 day simple moving average is $131.48. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The stock has a market capitalization of $234.00 billion, a PE ratio of 16.85, a PEG ratio of 2.52 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. The company's revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories's payout ratio is 29.57%.

Wall Street Analysts Forecast Growth

ABT has been the topic of several research reports. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and boosted their price target for the stock from $143.00 to $145.00 in a report on Friday, July 18th. Royal Bank Of Canada boosted their price target on Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a report on Tuesday, July 15th. Leerink Partners initiated coverage on Abbott Laboratories in a report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target on the stock. Mizuho boosted their price target on Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a report on Wednesday, July 16th. Finally, Raymond James Financial reduced their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $146.24.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.